GlassScriptPhysician profile
Edward Charles Mulligan
NPI 1881060283
$3,485.23
in general payments reported to CMS, 2019-2025
25 companies · $1,079 in 2025
The $1,079 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $20.74 · 2022: $288 · 2023: $1,059 · 2024: $1,039 · 2025: $1,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,176.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $612.97 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $417.42 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $377.61 | 2022-2025 | Rybelsus, Ozempic |
| Amgen INC. | $372.06 | 2023-2025 | Repatha, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $306.13 | 2023-2025 | Vaxelis, Gardasil 9, Vaxneuvance |
| Abbott Laboratories | $303.68 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Lilly USA, LLC | $273.91 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $104.49 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $104.41 | 2024-2025 | |
| Pfizer INC. | $82.01 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.86 | 2023-2025 | Jardiance |
| Nestle Healthcare Nutrition INC. | $65.96 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $45.11 | 2022-2023 | |
| Seqirus USA INC | $42.35 | 2022-2025 | Flucelvax, Fluad |
| Sanofi Pasteur INC. | $40.67 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $37.93 | 2024-2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $32.18 | 2023 | Austedo Xr, Austedo |
| Aimmune Therapeutics, INC. | $29.44 | 2024-2025 | Zenpep |
| Exact Sciences Corporation | $29.41 | 2025 | Cologuard Collection Kit |
| Almatica Pharma LLC | $26.10 | 2022 | |
| Novartis Pharmaceuticals Corporation | $25.18 | 2022 | |
| Xeris Pharmaceuticals, INC. | $24.29 | 2025 | Gvoke Hypopen |
| Nevro Corp. | $22.09 | 2024 | Senza |
| Janssen Pharmaceuticals, INC | $20.74 | 2020 | |
| Dexcom, INC. | $15.23 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Mulligan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.